Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
Arch Pharm Res
; 43(8): 765-772, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: covidwho-692878
ABSTRACT
A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Cloroquina
/
Infecciones por Coronavirus
/
Hidroxicloroquina
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Arch Pharm Res
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
S12272-020-01258-7
Similares
MEDLINE
...
LILACS
LIS